pharma · Acute Myeloid Leukemia · Advanced Hematologic Malignancy · FHTX
Foghorn Therapeutics
Foghorn Therapeutics is a pharma organization headquartered in Watertown, USA. It trades on NYSE under ticker FHTX. Primary therapeutic focus areas include Acute Myeloid Leukemia, Advanced Hematologic Malignancy, Metasta
Watertown, USA HQ
2016 Founded
124 Employees
Public company Type
FHTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Watertown, USA
- Founded
- 2016
- Employees
- 124
- Programs
- 5
- Drugs
- 2
- Patents
- 14
FHD-286
Phase 1 · small molecule · Metastatic Uveal Melanoma
FHD-286 for Metastatic Uveal Melanoma is a Phase 1 program (small_molecule) at Foghorn Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code FHD-286-C-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Foghorn Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Metastatic Uveal Melanoma
- Status
- terminated
- Trials
- 1